Abstract：This paper starts from the characteristics of innovation mechanism and innovation method, combines the current situation of China’s pharmaceutical industry, takes the Malerba industrial innovation system theory as the theoretical support, and constructs the technological innovation mechanism suitable for the current situation of China’s pharmaceutical industry, analyzes the innovation restriction mechanism structure of pharmaceutical enterprises from the aspects of the market structure and enterprise scale of the pharmaceutical industry, technological capital investment capacity, and innovative human capital investment capacity. From the strategic layout of pharmaceutical enterprises, the distribution of independent research and development forces, the operating mechanism that affects industry policies, the choice of pharmaceutical enterprises’ technological innovation mode, the patent system and the innovation and decision-making capabilities of pharmaceutical enterprises, the innovation operation mechanism structure of pharmaceutical enterprises are analyzed. Therefore, this article proposes measures to build a composite technological innovation entity, broaden the ideas for improving technological innovation capabilities, strengthen basic innovation research, highlight the ability of intellectual property to escort technological innovation, and accelerate the incubation of technological innovation achievements through multiple investment channels which are the key to the innovation mechanism of Chinese pharmaceutical enterprises.
徐扬1 徐朗2. 基于Malerba创新理论的我国制药企业技术创新机制研究[J]. 中国医药导报, 2020, 17(33): 170-173.
XU Yang1 XU Lang2. Research on technological innovation mechanism of Chinese pharmaceutical enterprises based on Malerba innovation theory. 中国医药导报, 2020, 17(33): 170-173.
2020, Vol. 17 
京公网安备 11010502046598号